Skip to main content
SpringerLink
Log in

Concerns About the Use of New Oral Anticoagulants for Stroke Prevention in Elderly Patients with Atrial Fibrillation

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The prevalence of atrial fibrillation (AF) and the embolic risk increase with age. Elderly AF patients are undertreated with vitamin K antagonists (VKA). The new oral anticoagulants (NOAC) dabigatran, rivaroxaban and apixaban have been shown to be non-inferior to VKA for stroke prevention in AF. We summarize the knowledge about primary and secondary stroke prevention by NOAC in AF patients >75 years of age. A literature search was carried out using the terms ‘dabigatran’, ‘rivaroxaban’, ‘apixaban’, ‘elderly’, ‘octogenarians’, ‘atrial fibrillation’ and ‘anticoagulation’ from 1998 to 2013. Randomized clinical trials, longitudinal studies, case series and case reports were included. Whereas studies investigating the use of VKA for stroke prevention in the 1990s were carried out by industry-independent institutions, all NOAC-investigating trials were sponsored by the manufacturers of the respective drugs. Frail elderly people were not represented in NOAC-investigating trials because of various exclusion criteria, and only one-third of patients were aged >75 years. A subgroup analysis from the dabigatran-investigating trial indicated that elderly patients might have a higher risk for extracranial bleeding complications with NOAC than with VKA. Further concerns about the use of NOAC in the elderly are the high prevalence of renal insufficiency in AF patients >75 years of age, the largely unknown risk of drug–drug and drug–food interactions, the lack of easily available laboratory monitoring tests of anticoagulant activity and the lack of an antidote. There is a need for independent studies comparing the efficacy and risk of side effects of NOAC with that of VKA in elderly AF patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N–9N.

    Article  PubMed  CAS  Google Scholar 

  2. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam Study. Eur Heart J. 2006;27:949–53.

    Article  PubMed  Google Scholar 

  3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.

    Article  PubMed  CAS  Google Scholar 

  4. Marengoni A, Qiu C, Winblad B, et al. Atrial fibrillation, stroke and dementia in the very old: a population-based study. Neurobiol Aging. 2011;32:1336–7.

    Article  PubMed  Google Scholar 

  5. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.

    Article  PubMed  Google Scholar 

  6. Scowcroft AC, Lee S, Mant J. Thromboprophylaxis of elderly patients with AF in the UK: an analysis using the General Practice Research Database (GPRD) 2000-2009. Heart. 2013;99:127–32.

    Article  PubMed  Google Scholar 

  7. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689–96.

    Article  PubMed  CAS  Google Scholar 

  8. Rosenman MB, Baker L, Jing Y, et al. Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records. Curr Med Res Opin. 2012;28:1407–14.

    Article  PubMed  CAS  Google Scholar 

  9. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493–503.

    Article  PubMed  CAS  Google Scholar 

  10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009;361:1139–51.

    Article  PubMed  CAS  Google Scholar 

  11. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011;365:883–91.

    Article  PubMed  CAS  Google Scholar 

  12. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011;365:981–92.

    Article  PubMed  CAS  Google Scholar 

  13. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.

    Article  PubMed  CAS  Google Scholar 

  14. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.

    Article  PubMed  CAS  Google Scholar 

  15. Höllerl F, Stöllberger C, Finsterer J. Renal function, P-gp-affecting drugs and new anticoagulants for stroke prevention. Int J Cardiol. 2013;168:576–7.

    Google Scholar 

  16. Hunchuck JE, Lake JD. Dabigatran for stroke prevention in all patients with atrial fibrillation? Pharmacotherapy. 2011;31:725–8.

    Article  PubMed  Google Scholar 

  17. Dowling TC, Wang ES, Ferrucci L, Sorkin JD. Glomerular filtration rate equations overestimate creatinine clearance in older individuals enrolled in the Baltimore longitudinal study on aging: impact on renal drug dosing. Pharmacotherapy. 2013;33:912–21.

    Google Scholar 

  18. Béné J, Saïd W, Rannou M, et al. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother. 2012;46:e14.

    Article  PubMed  Google Scholar 

  19. Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother. 2012;10:160–3.

    Article  PubMed  Google Scholar 

  20. Stöllberger C, Rakusan S, Wimpissinger FT, et al. Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention. Thromb Haemost. 2012;108:579–81.

    Article  PubMed  Google Scholar 

  21. Kernan L, Ito S, Shirazi F, et al. Fatal gastrointestinal hemorrhage after a single dose of dabigatran. Clin Toxicol (Phila). 2012;50:571–3.

    Article  PubMed  CAS  Google Scholar 

  22. Fellows SE, Rosini JM, Curtis JA, et al. Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency. J Emerg Med. 2013;44:e221–5.

    Article  PubMed  Google Scholar 

  23. Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46:e10.

    Article  PubMed  Google Scholar 

  24. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171:1285–6.

    Article  PubMed  Google Scholar 

  25. Dy EA, Shiltz DL. Hemopericardium and cardiac tamponade associated with dabigatran use. Ann Pharmacother. 2012;46:e18.

    Article  PubMed  Google Scholar 

  26. Barton CA, McMillian WD, Raza SS, et al. Hemopericardium in a patient treated with dabigatran etexilate. Pharmacotherapy. 2012;32:e103–7.

    Article  PubMed  Google Scholar 

  27. Lillo-Le Louët A, Wolf M, Soufir L, et al. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost. 2012;108:583–5.

    Article  PubMed  Google Scholar 

  28. Moore CH, Snashall J, Boniface K, et al. Spontaneous splenic hemorrhage after initiation of dabigatran (Pradaxa) for atrial fibrillation. Am J Emerg Med. 2012; 30:2082.e1–2.

    Google Scholar 

  29. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366:864–6.

    Article  PubMed  CAS  Google Scholar 

  30. Garber ST, Sivakumar W, Schmidt RH. Neurosurgical complications of direct thrombin inhibitors: catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg. 2012;116:1093–6.

    Article  PubMed  Google Scholar 

  31. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61:487–9.

    Article  PubMed  CAS  Google Scholar 

  32. Chen BC, Viny AD, Garlich FM, et al. Hemorrhagic complications associated with dabigatran use. Clin Toxicol (Phila). 2012;50:854–7.

    Article  PubMed  CAS  Google Scholar 

  33. Nguyen TM, Phelan MP, Werdich XQ, et al. Subconjunctival hemorrhage in a patient on dabigatran (Pradaxa). Am J Emerg Med. 2013;31:455.e3–5.

    Google Scholar 

  34. Dumkow LE, Voss JR, Peters M, et al. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm. 2012;69:1646–50.

    Article  PubMed  CAS  Google Scholar 

  35. Lal Y, Van Heukelom J. Dabigatran, a cause of hematologic emergency. Am J Med Sci. 2013;346:259.

    Google Scholar 

  36. Maddry JK, Amir MK, Sessions D, et al. Fatal dabigatran toxicity secondary to acute renal failure. Am J Emerg Med. 2013; 31:462.e1–2.

    Google Scholar 

  37. Freshour JE, Hudson JQ, Stevens AB, et al. Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance. Am J Health Syst Pharm. 2012;69:1184–6.

    Article  PubMed  CAS  Google Scholar 

  38. Stöllberger C, Zuntner G, Bastovansky A, Finsterer J. Cerebral hemorrhage under rivaroxaban. Int J Cardiol. 2013;167:e179–81.

    Google Scholar 

  39. Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76:455–66.

    Google Scholar 

  40. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug–drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38:448–58.

    Article  PubMed  CAS  Google Scholar 

  41. Marchetti S, Mazzanti R, Beijnen JH, et al. Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12:927–41.

    Article  PubMed  Google Scholar 

  42. Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med. 2011;22:597–602.

    Article  PubMed  Google Scholar 

  43. Sanders NA, Ganguly JA, Jetter TL, et al. Atrial fibrillation: an independent risk factor for nonaccidental falls in older patients. Pacing Clin Electrophysiol. 2012;35:973–9.

    Article  PubMed  Google Scholar 

  44. Solayar GN, Walsh PM, Mulhall KJ. The effect of a new direct factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin. BMC Musculoskelet Disord. 2011;12:247.

    Article  PubMed  CAS  Google Scholar 

  45. Stöllberger C, Finsterer J. Concerns about storage and application of dabigatran and rivaroxaban. Eur J Clin Pharmacol. 2013;69:739–40.

    Article  PubMed  Google Scholar 

  46. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18:527–39.

    PubMed  Google Scholar 

  47. Diug B, Evans S, Lowthian J, et al. The unrecognized psychosocial factors contributing to bleeding risk in warfarin therapy. Stroke. 2011;42:2866–71.

    Article  PubMed  Google Scholar 

  48. Spyropoulos AC, Douketis JD, Gerotziafas G, et al. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost. 2012;10:692–4.

    Article  PubMed  CAS  Google Scholar 

  49. Harenberg J, Marx S, Weiss C, et al. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost. 2012;10:1433–6.

    Article  PubMed  CAS  Google Scholar 

  50. Khan TI, Kamali F, Kesteven P, et al. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol. 2004;126:557–64.

    Article  PubMed  Google Scholar 

  51. Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med. 2004;164:2044–50.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Krankenanstalt Rudolfstiftung, Juchgasse 25, 1030, Wien, Austria

    Claudia Stöllberger & Josef Finsterer

  2. Steingasse 31/18, 1030, Wien, Austria

    Claudia Stöllberger

Authors
  1. Claudia Stöllberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josef Finsterer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudia Stöllberger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stöllberger, C., Finsterer, J. Concerns About the Use of New Oral Anticoagulants for Stroke Prevention in Elderly Patients with Atrial Fibrillation. Drugs Aging 30, 949–958 (2013). https://doi.org/10.1007/s40266-013-0119-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-013-0119-3

Keywords

Search

Navigation